The HA-2 Minor Histocompatibility Antigen Is Derived from a Diallelic Gene Encoding a Novel Human Class I Myosin Protein
暂无分享,去创建一个
J. Shabanowitz | D. Hunt | V. Engelhard | R. Pierce | L. Eisenlohr | M. Wilke | T. Golovina | T. Mutis | M. Pettenati | E. Goulmy | J. Pool | E. Field | C. V. Kap-Herr | Erin D. Field
[1] S. Karthickeyan. Gene Mapping by Fluorescence In situ Hybridization (Fish) in Cattle and Buffaloes , 2002 .
[2] J. Shabanowitz,et al. The Immunogenicity of a New Human Minor Histocompatibility Antigen Results from Differential Antigen Processing , 2001, The Journal of experimental medicine.
[3] S. Carr,et al. Mass Spectrometry in Biology & Medicine , 2000, Humana Press.
[4] J. Shabanowitz,et al. Subfemtomole MS and MS/MS peptide sequence analysis using nano-HPLC micro-ESI fourier transform ion cyclotron resonance mass spectrometry. , 2000, Analytical chemistry.
[5] V. Engelhard,et al. The Density of Peptides Displayed by Dendritic Cells Affects Immune Responses to Human Tyrosinase and gp100 in HLA-A2 Transgenic Mice1 , 2000, The Journal of Immunology.
[6] J. Shabanowitz,et al. Sequencing the Primordial Soup , 2000 .
[7] J. Shabanowitz,et al. Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. , 1999, Journal of immunology.
[8] F. Locatelli,et al. Resolution of immune haemolytic anaemia with allogeneic bone marrow transplantation after an unsuccessful autograft , 1999, British journal of haematology.
[9] S Uebel,et al. Specificity of the proteasome and the TAP transporter. , 1999, Current opinion in immunology.
[10] R. Verdijk,et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. , 1999, Blood.
[11] Bin Wang,et al. Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[12] B. Smith,et al. Bone marrow transplantation for autoimmune diseases. , 1999, Current opinion in oncology.
[13] J. Shabanowitz,et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. , 1998, Science.
[14] V. Mermall,et al. Unconventional myosins in cell movement, membrane traffic, and signal transduction. , 1998, Science.
[15] A. Marmont. Stem cell transplantation for severe autoimmune diseases: progress and problems. , 1998, Haematologica.
[16] L. Eisenlohr,et al. Murine Transporter Associated with Antigen Presentation (TAP) Preferences Influence Class I–restricted T Cell Responses , 1997, The Journal of experimental medicine.
[17] S Uebel,et al. Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[18] E. Goulmy. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy , 1997, Immunological reviews.
[19] J. Snowden,et al. Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin’s lymphoma , 1997, Bone Marrow Transplantation.
[20] A. Marmont. Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. , 1997, The Journal of rheumatology. Supplement.
[21] R. A. Myers,et al. Gene mapping by fluorescence in situ hybridization. , 1996 .
[22] A Sette,et al. The peptide-binding motif for the human transporter associated with antigen processing , 1995, The Journal of experimental medicine.
[23] F Koning,et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. , 1995, Science.
[24] M. Feltkamp,et al. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. , 1995, Journal of immunology.
[25] M. Mooseker,et al. Cloning and mRNA expression of human unconventional myosin-IC. A homologue of amoeboid myosins-I with a single IQ motif and an SH3 domain. , 1994, Journal of molecular biology.
[26] T. Hasson,et al. Identification and overlapping expression of multiple unconventional myosin genes in vertebrate cell types. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[27] Günter J. Hämmerling,et al. Selectivity of MHC-encoded peptide transporters from human, mouse and rat , 1994, Nature.
[28] J. Sidney,et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.
[29] A. Bakker,et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. , 1992, Journal of immunology.
[30] E. Goulmy,et al. Minor histocompatibility antigens, defined by graft‐vs.‐host disease‐derived cytotoxic T lymphocytes, show variable expression on human skin cells , 1991, European journal of immunology.
[31] H. Rammensee,et al. Identification of classical minor histocompatibility antigen as cell-derived peptide , 1990, Nature.
[32] L. Sherman,et al. Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response , 1989, The Journal of experimental medicine.
[33] P. Parham,et al. Cytotoxic T lymphocyte-defined epitope differences between HLA-A2.1 and HLA-A2.2 map to two distinct regions of the molecule. , 1988, Journal of immunology.
[34] M. Daha,et al. Endothelial cell lysis induced by lymphokine‐activated human peripheral blood mononuclear cells , 1987, European journal of immunology.
[35] S. Spicer,et al. Tissue culture of human kidney epithelial cells of proximal tubule origin. , 1984, Kidney international.
[36] P. Parham,et al. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. , 1981, Human immunology.
[37] M. C. Green,et al. Catalog of mutant genes and polymorphic loci. , 1981 .
[38] F. Greenwood,et al. THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.